Bemarituzumab
Based on 1 Customer Validation
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.82%
- No. CAS: 1952272-74-0
- Peso molecular:143.86 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Human IgG1 kappa
Human
FGFR2/CD332
Bemarituzumab (0.001-100 μg/mL, 30 min) inhibits FGF7-induced FGFR2 phosphorylation and cell proliferation in a concentration-dependent manner in the SNU-16 human gastric cancer cells, reaching a maximal value at ≥6.25 μg/mL[2].
Bemarituzumab exhibits immune cell-mediated killing of tumor cells overexpressing FGFR2b[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Bemarituzumab (5 mg/kg; i.p.; twice a week) combined with 5-fluorouracil (HY-90006) and Oxaliplatin (HY-17371) significantly inhibits tumor growth more than monotherapy and does not increase chemotherapy-related toxicity in the OCUM-2M gastric cancer xenograft model[2].
Bemarituzumab (10 mg/kg; i.p.; biweekly) significantly reduces tumor burden, recruits NK cells, and increases PD-L1-expressing cells and CD3-positive T cells in the syngeneic 4T1 mouse mammary tumor model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CB17 SCID mice (7-8 weeks old), xenograft model of OCUM-2M human gastric cancer cells[2]
-
Dosage:1 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg (in PBS)
-
Administration:Intravenous injection, twice a week
-
Result:Inhibited tumor growth in a dose-dependent manner.
Inhibited and regressed tumor growth starting from a dose of 1 mg/kg.
Caused complete tumor regression in 1/15 mice at the 1.5 mg/kg and 2 mg/kg doses, 4/15 mice at the 3 mg/kg dose, and 6/15 mice at the 5 mg/kg dose by day 42.
-
Animal Model:Tg-ArcSwe transgenic mice (11-14 months old) harboring the APP Arctic mutation[3]
-
Dosage:10 mg/kg
-
Administration:i.p., once weekly, for 4/13 weeks
-
Result:Achieved brain amyloid-β (Aβ) protofibril and cerebrospinal fluid (CSF) Aβ protofibrils/oligomers reduction.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized FGFR-2 alpha (IIIb) Protein, Human (HEK293, His, HY-P76336) can bind Bemarituzumab. The EC50 for this effect is 5.673 ng/mL.
Chemical Information
-
No. CAS 1952272-74-0
-
Appearance Liquid
-
Peso molecular 143.86 kDa
-
Color Colorless to light yellow
-
SMILES
[Bemarituzumab]
-
Synonyms
AMG-552; FPA-144
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Daniel Vt Catenacci, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun;15(18):2073-2082. [Content Brief]
[2]. Xiang H, et al. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021 Jan-Dec;13(1):1981202. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bemarituzumab Related Classifications
HY-P99010 Related Classifications
Powered by Bioz